Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 08:11pm EST
Logo of healthcare company Johnson & Johnson is seen in Zug

(Reuters) - A Missouri jury on Thursday ordered Johnson & Johnson to pay a record $4.69 billion (3.55 billion pounds) to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

The verdict is the largest J&J has faced to date over allegations that its talc-based products cause cancer.

The company is battling some 9,000 talc cases. J&J denies both that its talc products cause cancer and that they ever contained asbestos. It says decades of studies show its talc to be safe and has successfully overturned previous talc verdicts on technical legal grounds.

Thursday's massive verdict, handed down in the Circuit Court of the City of St. Louis, was comprised of $550 million in compensatory damages and $4.14 billion in punitive damages, according to an online broadcast of the trial by Courtroom View Network.

J&J in a statement called the trial "fundamentally unfair" and said it would appeal the decision.

J&J shares fell $1.31, or 1 percent, to $126.45 in after-hours trading following the punitive damages award. They had risen $1.52 during regular trading.

The jury's decision followed more than five weeks of testimony by nearly a dozen experts on both sides.

The women and their families said decades-long use of Baby Powder and other cosmetic talc products caused their diseases. They allege the company knew its talc was contaminated with asbestos since at least the 1970s but failed to warn consumers about the risks.

"Johnson & Johnson is deeply disappointed in the verdict, which was the product of a fundamentally unfair process," the company said in a statement. The company said it remained confident that its products do not contain asbestos or cause cancer.

"Every verdict against Johnson & Johnson in this court that has gone through the appeals process has been reversed and the multiple errors present in this trial were worse than those in the prior trials which have been reversed," J&J added, saying that it would pursue all available appellate remedies.

J&J has successfully overturned talc verdicts in the past, with appeals courts pointing to a 2017 decision by the U.S. Supreme Court that limits where personal injury lawsuits can be filed.

Of the 22 women in the St. Louis trial, 17 were from outside Missouri, a state generally regarded as friendly towards plaintiffs. The practice of combining plaintiffs in such jurisdictions, commonly criticized as "forum shopping" by defendants, will be challenged on appeal.

Mark Lanier, the lawyer for the women, in a statement following the verdict called on J&J to pull its talc products from the market "before causing further anguish, harm, and death from a terrible disease."

"If J&J insists on continuing to sell talc, they should mark it with a serious warning," Lanier said.

The majority of the lawsuits that J&J faces involve claims that talc itself caused ovarian cancer, but a smaller number of cases allege that contaminated talc caused mesothelioma, a tissue cancer closely linked to asbestos exposure.

The cases that went to trial in St. Louis effectively combine those claims by alleging asbestos-contaminated talc caused ovarian cancer.

Previous talc trials have produced verdicts as large as $417 million. But that 2017 verdict by a California jury, as well as other verdicts in Missouri, was overturned on appeal, and challenges to at least another five verdicts are pending.

The U.S. Food and Drug Administration commissioned a study of various talc samples from 2009 to 2010, including of J&J's Baby Powder. No asbestos was found in any of the talc samples, the agency said https://bit.ly/2L5oXJP.

But Lanier during the trial told jurors that the agency and other laboratories and J&J have used flawed testing methods that did not allow for the proper detection of asbestos fibres.

Talc, the world's softest rock, is a mineral closely linked to asbestos and the two substances can appear in close proximity in the earth.

Plaintiffs claim the two can become intermingled in the mining process, making it impossible to remove the carcinogenic substance. J&J denies those allegations, saying rigorous testing and purification processes ensure its talc is clean.

(Reporting by Tina Bellon in New York; editing by Leslie Adler and Rosalba O'Brien)

By Tina Bellon

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
03:51aJOHNSON & JOHNSON : puts up strong profit and revenue in 4Q
AQ
03:50aGENMAB : Announces 2018 Net Sales Figures for DARZALEX (Daratumumab)
AQ
01:49aJOHNSON & JOHNSON : J&J's Generic Rivals Pressure Its Sales
DJ
01:48aJOHNSON & JOHNSON : J&J's Generic Rivals Pressure Its Sales
DJ
01/22MARKET SNAPSHOT: Stocks Snap Four-day Winning Streak As Trade Worries Fester
DJ
01/22Wall Street drops as economic outlook, corporate forecasts sour
RE
01/22Wall Street ends four-day rally as economic outlook, corporate forecasts sour
RE
01/22Wall Street drops over 1.5 percent as global growth worries resurface
RE
01/22JOHNSON & JOHNSON : Expects Sales Growth to Slow -- Update
DJ
01/22JOHNSON & JOHNSON : to Pay $120 Million to Settle Multi-State Hip Implant Claims
DJ
More news
Financials ($)
Sales 2019 82 263 M
EBIT 2019 26 653 M
Net income 2019 20 325 M
Finance 2019 1 989 M
Yield 2019 2,96%
P/E ratio 2019 16,90
P/E ratio 2020 15,83
EV / Sales 2019 4,18x
EV / Sales 2020 3,89x
Capitalization 345 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 144 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.27%345 439
PFIZER-3.16%245 166
NOVARTIS4.88%225 489
ROCHE HOLDING LTD.5.59%221 685
MERCK AND COMPANY-0.76%197 187
AMGEN3.76%128 706